SPRB — Spruce Biosciences, Inc.

Summary of Spruce Biosciences Q1 2023 Earnings Call

1. Key Financial Results and Metrics

• As of December 31, 2024, Spruce reported cash and cash equivalents of $38.8 million.
• The company expects its cash runway to fund operations through the end of 2025, focusing solely on the development of Tralesinidase Alfa Enzyme Replacement Therapy (TA-ERT).
• There are 42.2 million shares of common stock outstanding, increasing to 60.7 million on a fully diluted basis.
• The company anticipates needing approximately $60 million in incremental capital to reach potential approval for TA-ERT, with about half of that required for the BLA submission.

2. Strategic Updates and Business Highlights

• Spruce announced a new corporate strategy focused on developing TA-ERT for the treatment of MPS IIIB, a severe pediatric neurodegenerative disease.
• The company has acquired TA-ERT and plans to submit a Biologics License Application (BLA) in the first half of 2026.
• TA-ERT has received fast track designation, rare pediatric disease designation, and orphan drug designation in both the U.S. and EU.
• The FDA has agreed on the use of heparan sulfate as a biomarker for accelerated approval and has approved the design of a Phase 3 confirmatory trial involving 14 patients.

3. Forward Guidance and Outlook

• Spruce aims to initiate the confirmatory trial prior to the BLA submission and expects to file for accelerated approval based on existing clinical data.
• The company plans to build a specialized commercial organization with a targeted field team of 5 to 10 people to support the launch of TA-ERT.
• The estimated patient population for MPS IIIB in the U.S. is around 135, with a potential market expansion to other developed regions.

4. Bad News, Challenges, or Points of Concern

• The previous development program for CAH was discontinued due to failure to meet primary efficacy measures, leading to a strategic review and a shift in focus to MPS IIIB.
• The company faces financial pressures and will need to secure additional funding to continue operations beyond 2025.
• There is uncertainty regarding the market environment and investor sentiment, which could impact fundraising efforts.
• The prior sponsor of TA-ERT discontinued the program due to financial constraints, raising concerns about the continuity of patient access and ongoing treatment.

5. Notable Q&A Insights

• Management expressed confidence in the FDA's commitment to the accelerated approval pathway, citing precedents set by other companies in the MPS space.
• The company is still determining the exact number of eligible patients for TA-ERT treatment and will implement patient mapping and early access programs.
• There is a focus on ensuring that the confirmatory trial meets FDA requirements, particularly regarding the primary neurocognitive outcome.
• Pricing for TA-ERT will be influenced by the competitive landscape, particularly by other treatments for MPS diseases, with expectations of a high price point due to the drug's significant therapeutic potential.

Overall, Spruce Biosciences is transitioning into a new phase focused on MPS IIIB, with strategic plans for development and commercialization, while navigating financial challenges and the complexities of regulatory pathways.